Fenofibrate Restores Fatty Acid Oxidation in CPT2-Deficient Placenta to Attenuate Fetal Growth Restriction [ID 1114]

INTRODUCTION: Lipid metabolic homeostasis is essential for healthy embryonic growth and development. Carnitine palmitoyltransferase 2 (CPT2), a key regulator of mitochondrial fatty acid β-oxidation, plays a critical role in this process, yet its involvement in fetal growth restriction (FGR) remains insufficiently explored. METHODS: Human serum and placenta, FGR mice, and trophoblast cells were used. siRNA transfection was utilized for gene knockdown. Lipidomics and proteomics were performed for mechanism exploration. The assays of proliferation, migration, and invasion were employed to assess the cellular biological functions. To evaluate the growth status in mice, the weight of the newborn mice, the placental efficiency, and histological characteristics were examined. RESULTS: Results demonstrate that both FGR patients and mouse models exhibit increased maternal serum and placental lipid accumulation, accompanied by significantly decreased placental CPT2 expression and diminished fatty acid oxidation. Silencing CPT2 disrupts trophoblast cell metabolism, proliferation, migration, and invasion, highlighting its importance in cellular function. Placental PPARα expression is also notably reduced in FGR, further compromising lipid metabolism. In FGR mice, fetal weight and placental efficiency are markedly reduced. Importantly, administration of fenofibrate, a PPARα agonist, significantly upregulates CPT2 expression, restores placental lipid oxidative capacity, and improves fetal growth and placental function in FGR models. CONCLUSIONS/IMPLICATIONS: Findings underscore the pivotal role of CPT2 in placental lipid metabolism and trophoblast biology, directly affecting fetal development. Targeting the PPARα–CPT2 axis with fenofibrate emerges as a promising and effective therapeutic approach for improving outcomes in FGR, offering a new direction for clinical intervention in this challenging pregnancy complication.

Authors

Institutions

Publication Details

Journal
Obstetrics and Gynecology
Published
2026-04-30
DOI
https://doi.org/10.1097/aog.0000000000006268.09
Primary Topic
Gestational Diabetes Research and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Fenofibrate Restores Fatty Acid Oxidation in CPT2-Deficient Placenta to Attenuate Fetal Growth Restriction [ID 1114]

Xuening Li, Yuan Wei
Obstetrics and Gynecology
Gestational Diabetes Research and Management
article

Fenofibrate Restores Fatty Acid Oxidation in CPT2-Deficient Placenta to Attenuate Fetal Growth Restriction [ID 1114]

Xuening Li, Yuan Wei
article en

Abstract

INTRODUCTION: Lipid metabolic homeostasis is essential for healthy embryonic growth and development. Carnitine palmitoyltransferase 2 (CPT2), a key regulator of mitochondrial fatty acid β-oxidation, plays a critical role in this process, yet its involvement in fetal growth restriction (FGR) remains insufficiently explored. METHODS: Human serum and placenta, FGR mice, and trophoblast cells were used. siRNA transfection was utilized for gene knockdown. Lipidomics and proteomics were performed for mechanism exploration. The assays of proliferation, migration, and invasion were employed to assess the cellular biological functions. To evaluate the growth status in mice, the weight of the newborn mice, the placental efficiency, and histological characteristics were examined. RESULTS: Results demonstrate that both FGR patients and mouse models exhibit increased maternal serum and placental lipid accumulation, accompanied by significantly decreased placental CPT2 expression and diminished fatty acid oxidation. Silencing CPT2 disrupts trophoblast cell metabolism, proliferation, migration, and invasion, highlighting its importance in cellular function. Placental PPARα expression is also notably reduced in FGR, further compromising lipid metabolism. In FGR mice, fetal weight and placental efficiency are markedly reduced. Importantly, administration of fenofibrate, a PPARα agonist, significantly upregulates CPT2 expression, restores placental lipid oxidative capacity, and improves fetal growth and placental function in FGR models. CONCLUSIONS/IMPLICATIONS: Findings underscore the pivotal role of CPT2 in placental lipid metabolism and trophoblast biology, directly affecting fetal development. Targeting the PPARα–CPT2 axis with fenofibrate emerges as a promising and effective therapeutic approach for improving outcomes in FGR, offering a new direction for clinical intervention in this challenging pregnancy complication.

Obstetrics and GynecologyVol. 147(5S)
Peking University (CN), Peking University Third Hospital (CN)
Openalex Percentile: Top 6%
Gestational Diabetes Research and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.